Hospital
Prospect Waterbury, INC.
Prospect Waterbury, INC. was paid $84.62M by Medicaid between Jan 2018 and Dec 2024, across 435 billing codes. Its largest line is 99285, emergency room visit (most serious) — 24% of everything it billed.
33Billing provider infoPROSPECT WATERBURY, INC.
WATERBURY, CT 06708
WATERBURY, CT 06708
33aNPI1477902641assigned 06/08/2016
33bProvider typeGeneral Acute Care Hospital
28Total paid$84.62M
24GClaims2,313,484
24DCodes billed435
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Connecticut
Rank by total paid#6 of 18
Median peer was paid$15.60M
This provider vs. median5.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ELDERS, ROBERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 371,582 | $13.64M | |
| 2019 | 398,478 | $13.68M | |
| 2020 | 309,955 | $11.21M | |
| 2021 | 348,416 | $12.70M | |
| 2022 | 329,059 | $11.82M | |
| 2023 | 293,299 | $10.80M | |
| 2024incomplete | 262,695 | $10.76M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 24% | 38,240 | 33,282 | $20.08M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 46,915 | 41,247 | $14.18M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 47,800 | 42,874 | $9.83M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.6% | 27,110 | 23,242 | $3.92M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 3.0% | 4,762 | 4,379 | $2.58M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 9,810 | 8,805 | $2.01M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.2% | 7,754 | 7,165 | $1.89M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.6% | 9,631 | 7,829 | $1.31M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 13,368 | 11,782 | $1.21M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.4% | 1,604 | 1,454 | $1.16M |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 21,500 | 19,230 | $1.13M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 9,168 | 8,507 | $1.12M |
423 more codes
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | 1.2% | 8,292 | $1.03M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 7,462 | $978K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.1% | 13,233 | $970K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 8,670 | $970K |
| S9480 | Intensive outpatient psychiatric services, per diem | 1.1% | 7,744 | $962K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.1% | 23,746 | $912K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 6,274 | $911K |
| 58661 | 1.1% | 176 | $891K | |
| 93975 | <1% | 3,430 | $724K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 34,480 | $705K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 15,957 | $697K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 17,773 | $692K |
| 71045 | Radiologic examination, chest; single view | <1% | 12,010 | $561K |
| 80053 | Comprehensive metabolic panel | <1% | 82,373 | $517K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,986 | $457K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 13,543 | $378K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 13,519 | $378K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,560 | $343K |
| 86900 | <1% | 12,805 | $332K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 182,325 | $328K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 16,134 | $308K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 30,112 | $307K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 441 | $303K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 559 | $297K |
| 93458 | <1% | 244 | $264K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,937 | $247K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,764 | $247K |
| 80061 | Lipid panel | <1% | 27,552 | $246K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,817 | $240K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 471 | $238K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 46,734 | $223K |
| 70486 | <1% | 1,554 | $222K | |
| 95816 | <1% | 1,320 | $217K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,099 | $217K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 981 | $205K |
| 59025 | Fetal non-stress test | <1% | 1,388 | $182K |
| 71250 | <1% | 3,305 | $172K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 103,733 | $171K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 30,549 | $167K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 16,313 | $163K |
| 93971 | <1% | 2,243 | $158K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,570 | $157K |
| 95811 | <1% | 234 | $154K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,663 | $143K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,096 | $142K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 16,903 | $137K |
| 93017 | <1% | 6,438 | $137K | |
| 70498 | <1% | 1,017 | $132K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,505 | $122K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,974 | $121K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 41,819 | $118K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 6,508 | $115K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,898 | $110K |
| 87625 | <1% | 3,901 | $99K | |
| 58571 | <1% | 15 | $99K | |
| 87536 | <1% | 1,487 | $96K | |
| 72100 | <1% | 3,965 | $94K | |
| J2357 | Injection, omalizumab, 5 mg | <1% | 649 | $89K |
| 82607 | <1% | 9,844 | $86K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 15,775 | $86K |
| 58558 | <1% | 43 | $84K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,064 | $83K |
| 82570 | <1% | 26,874 | $82K | |
| 86480 | <1% | 1,879 | $80K | |
| 85027 | <1% | 33,388 | $79K | |
| 36416 | <1% | 21,814 | $78K | |
| 84439 | <1% | 13,421 | $77K | |
| 71271 | <1% | 688 | $71K | |
| 97602 | <1% | 513 | $62K | |
| 86803 | <1% | 6,095 | $62K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 4,638 | $60K |
| C1769 | Guide wire | <1% | 1,316 | $56K |
| 73560 | <1% | 5,081 | $55K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,762 | $54K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15,739 | $53K |
| 76770 | <1% | 580 | $51K | |
| 86360 | <1% | 1,413 | $51K | |
| 86235 | <1% | 2,553 | $50K | |
| 86618 | <1% | 5,014 | $49K | |
| 93970 | <1% | 389 | $48K | |
| 73130 | <1% | 3,903 | $48K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 143 | $46K |
| 73610 | <1% | 3,375 | $44K | |
| 73030 | <1% | 4,011 | $44K | |
| 82947 | <1% | 19,973 | $42K | |
| 83655 | <1% | 3,905 | $42K | |
| 80076 | <1% | 18,724 | $39K | |
| 88304 | <1% | 2,124 | $39K | |
| 76536 | <1% | 508 | $39K | |
| 73630 | <1% | 3,292 | $39K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 831 | $38K |
| 82746 | <1% | 4,574 | $38K | |
| 82728 | <1% | 4,522 | $37K | |
| 87070 | <1% | 6,549 | $37K | |
| 88342 | <1% | 1,317 | $36K | |
| 87077 | <1% | 8,383 | $36K | |
| 84403 | <1% | 1,882 | $35K | |
| 87340 | <1% | 4,740 | $35K | |
| 81001 | <1% | 30,876 | $34K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 378 | $33K |
| 73502 | <1% | 2,574 | $32K | |
| 84153 | <1% | 3,104 | $31K | |
| 83970 | <1% | 1,378 | $31K | |
| 73110 | <1% | 1,975 | $29K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,701 | $29K |
| 0001A | <1% | 1,081 | $29K | |
| 84480 | <1% | 2,867 | $27K | |
| 86318 | <1% | 2,467 | $27K | |
| 83550 | <1% | 4,886 | $26K | |
| 86592 | <1% | 7,214 | $26K | |
| 93976 | <1% | 274 | $25K | |
| 93308 | <1% | 209 | $25K | |
| 87081 | <1% | 9,163 | $22K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 694 | $22K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 82 | $22K |
| 86038 | <1% | 2,795 | $22K | |
| 83540 | <1% | 5,278 | $21K | |
| 78431 | <1% | 68 | $20K | |
| 87186 | <1% | 4,677 | $19K | |
| 70496 | <1% | 341 | $18K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,378 | $18K |
| 82043 | <1% | 5,448 | $17K | |
| G0378 | Hospital observation service, per hour | <1% | 9,627 | $16K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 151 | $16K |
| 85651 | <1% | 8,481 | $15K | |
| 72040 | <1% | 857 | $15K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 532 | $15K |
| 85610 | <1% | 28,956 | $15K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 154 | $15K |
| 73562 | <1% | 734 | $15K | |
| 88307 | <1% | 780 | $14K | |
| 74018 | <1% | 537 | $14K | |
| 83880 | <1% | 11,502 | $14K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 215 | $14K |
| 86800 | <1% | 1,511 | $14K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 144 | $14K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 25 | $14K |
| 83721 | <1% | 2,525 | $14K | |
| 73070 | <1% | 1,292 | $13K | |
| 84270 | <1% | 765 | $13K | |
| 0002A | <1% | 463 | $12K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 979 | $12K |
| 86706 | <1% | 1,682 | $12K | |
| G0144 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system, under physician supervision | <1% | 905 | $12K |
| 97161 | <1% | 1,683 | $12K | |
| 86376 | <1% | 1,421 | $11K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 11,317 | $11K |
| 83735 | <1% | 17,030 | $11K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 159 | $11K |
| 86617 | <1% | 1,170 | $11K | |
| 87522 | Neg quan hep c or qual rna | <1% | 328 | $11K |
| 86200 | <1% | 1,843 | $11K | |
| 86140 | <1% | 5,108 | $11K | |
| 88112 | <1% | 733 | $10K | |
| 93307 | <1% | 77 | $10K | |
| 83525 | <1% | 1,155 | $10K | |
| 72070 | <1% | 679 | $10K | |
| 90675 | <1% | 37 | $9K | |
| 81003 | <1% | 25,760 | $9K | |
| 70491 | <1% | 60 | $9K | |
| 84702 | <1% | 5,055 | $8K | |
| 86703 | <1% | 975 | $8K | |
| 86334 | <1% | 722 | $8K | |
| 97162 | <1% | 577 | $8K | |
| 80074 | <1% | 245 | $8K | |
| 86431 | <1% | 2,562 | $7K | |
| 73590 | <1% | 739 | $7K | |
| 81025 | <1% | 19,103 | $7K | |
| 84484 | <1% | 32,916 | $7K | |
| 72131 | <1% | 126 | $7K | |
| 83516 | <1% | 682 | $7K | |
| 84481 | <1% | 577 | $7K | |
| 82550 | <1% | 5,058 | $7K | |
| 84146 | <1% | 468 | $6K | |
| 73140 | <1% | 503 | $6K | |
| 93880 | <1% | 97 | $6K | |
| 86003 | <1% | 128 | $6K | |
| 82652 | <1% | 216 | $6K | |
| 83690 | <1% | 22,819 | $6K | |
| 72050 | <1% | 205 | $6K | |
| 82565 | <1% | 4,495 | $6K | |
| 85730 | <1% | 7,365 | $6K | |
| 85018 | <1% | 5,163 | $6K | |
| 83021 | <1% | 371 | $6K | |
| 82731 | <1% | 275 | $5K | |
| 96376 | <1% | 3,395 | $5K | |
| 10060 | <1% | 39 | $5K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 689 | $5K |
| 12001 | <1% | 921 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,820 | $5K |
| 85007 | <1% | 3,425 | $5K | |
| 86696 | <1% | 304 | $4K | |
| 86160 | <1% | 312 | $4K | |
| 80051 | <1% | 2,251 | $4K | |
| 10061 | <1% | 13 | $4K | |
| 87205 | <1% | 2,174 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 11,877 | $4K |
| 82150 | <1% | 3,635 | $4K | |
| 82040 | <1% | 1,185 | $3K | |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 297 | $3K |
| 82105 | <1% | 214 | $3K | |
| 84460 | <1% | 1,913 | $3K | |
| 83001 | <1% | 212 | $3K | |
| 87088 | <1% | 842 | $3K | |
| 74174 | <1% | 14 | $3K | |
| 86901 | <1% | 12,778 | $3K | |
| 80164 | <1% | 439 | $3K | |
| 84100 | <1% | 9,628 | $3K | |
| 82784 | <1% | 411 | $3K | |
| 87075 | <1% | 550 | $3K | |
| 84550 | <1% | 3,062 | $3K | |
| 86255 | <1% | 312 | $3K | |
| 84156 | <1% | 1,731 | $3K | |
| 86704 | <1% | 313 | $2K | |
| 97597 | <1% | 35 | $2K | |
| 76641 | <1% | 34 | $2K | |
| 71101 | <1% | 351 | $2K | |
| 83020 | <1% | 207 | $2K | |
| 80050 | General health panel | <1% | 719 | $2K |
| 87040 | <1% | 5,101 | $2K | |
| 86328 | <1% | 80 | $2K | |
| 86225 | <1% | 218 | $2K | |
| 73090 | <1% | 299 | $2K | |
| 84703 | <1% | 8,189 | $2K | |
| 87634 | <1% | 39 | $2K | |
| 12002 | <1% | 188 | $2K | |
| 84450 | <1% | 1,845 | $2K | |
| 87631 | <1% | 1,076 | $1K | |
| 85379 | <1% | 4,480 | $1K | |
| 84165 | <1% | 320 | $1K | |
| 83605 | <1% | 9,488 | $1K | |
| 86695 | <1% | 143 | $1K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 480 | $1K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 14 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,861 | $1K |
| 96415 | <1% | 28 | $1K | |
| 0031A | <1% | 56 | $1K | |
| 82977 | <1% | 247 | $1K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 314 | $1K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 4,010 | $1K |
| 97116 | <1% | 167 | $1K | |
| 87430 | <1% | 5,802 | $1K | |
| 86665 | <1% | 78 | $1K | |
| J3490 | Unclassified drugs | <1% | 112,598 | $1K |
| 84134 | <1% | 137 | $1K | |
| 86735 | <1% | 99 | $1K | |
| 0012A | <1% | 60 | $1K | |
| 74019 | <1% | 41 | $1K | |
| 86850 | <1% | 8,872 | $1K | |
| 86708 | <1% | 106 | $1K | |
| 88302 | <1% | 303 | $1K | |
| 12011 | <1% | 324 | $972.03 | |
| 84432 | <1% | 88 | $966.42 | |
| 86765 | <1% | 90 | $935.56 | |
| 36430 | <1% | 14 | $917.72 | |
| 72170 | <1% | 116 | $879.57 | |
| 85014 | <1% | 531 | $874.62 | |
| 86790 | <1% | 570 | $838.17 | |
| 96367 | <1% | 15 | $837.84 | |
| C1781 | Mesh (implantable) | <1% | 13 | $827.68 |
| 86308 | <1% | 799 | $818.25 | |
| 86039 | <1% | 112 | $755.26 | |
| 84132 | <1% | 417 | $712.14 | |
| 83002 | <1% | 56 | $712.07 | |
| 86920 | <1% | 112 | $682.58 | |
| 82140 | <1% | 160 | $668.16 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 14 | $601.80 |
| 80177 | <1% | 100 | $564.23 | |
| 88142 | <1% | 44 | $563.34 | |
| 84112 | <1% | 66 | $553.68 | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 37 | $553.35 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,597 | $540.00 |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 34 | $519.18 |
| 82247 | <1% | 222 | $508.54 | |
| 85041 | <1% | 218 | $506.00 | |
| 76642 | <1% | 12 | $490.90 | |
| 86664 | <1% | 39 | $467.52 | |
| 87427 | <1% | 50 | $412.20 | |
| 86666 | <1% | 40 | $408.24 | |
| 87329 | <1% | 43 | $377.85 | |
| 87328 | <1% | 43 | $377.85 | |
| 82803 | <1% | 599 | $375.52 | |
| 82670 | <1% | 15 | $373.52 | |
| 90715 | <1% | 2,520 | $338.31 | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 35 | $318.79 |
| 84520 | <1% | 2,521 | $313.38 | |
| 82248 | <1% | 381 | $310.60 | |
| 74420 | <1% | 30 | $303.66 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 45,473 | $289.62 |
| 76870 | <1% | 42 | $274.52 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17,087 | $262.69 |
| 83615 | <1% | 239 | $257.90 | |
| 97165 | <1% | 61 | $253.94 | |
| 86709 | <1% | 30 | $247.25 | |
| 84155 | <1% | 260 | $240.01 | |
| 87046 | <1% | 39 | $239.73 | |
| 93225 | <1% | 43 | $222.54 | |
| 87045 | <1% | 39 | $216.48 | |
| 87102 | <1% | 29 | $192.48 | |
| 86317 | <1% | 15 | $186.16 | |
| 0011A | <1% | 25 | $186.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 36 | $182.91 |
| 51702 | <1% | 33 | $176.92 | |
| 86812 | <1% | 15 | $172.55 | |
| 73552 | <1% | 59 | $164.53 | |
| 85045 | <1% | 77 | $157.94 | |
| 82785 | <1% | 15 | $157.30 | |
| 86753 | <1% | 18 | $153.79 | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 93 | $152.85 |
| 83921 | <1% | 13 | $141.48 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 28,531 | $136.73 |
| 84145 | <1% | 105 | $127.90 | |
| 82010 | <1% | 801 | $124.30 | |
| 76937 | <1% | 41 | $121.00 | |
| 80143 | <1% | 1,377 | $101.64 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,497 | $92.16 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 4,912 | $89.70 |
| 73060 | <1% | 13 | $88.74 | |
| J2704 | Injection, propofol, 10 mg | <1% | 13,254 | $82.45 |
| 88341 | <1% | 502 | $80.60 | |
| 80320 | <1% | 4,506 | $80.25 | |
| 87420 | <1% | 528 | $80.15 | |
| 71100 | <1% | 15 | $69.15 | |
| 86705 | <1% | 12 | $67.50 | |
| 82085 | <1% | 15 | $64.89 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 3,541 | $63.84 |
| 84436 | <1% | 16 | $59.04 | |
| 80179 | <1% | 1,299 | $57.91 | |
| 87220 | <1% | 14 | $56.98 | |
| 82950 | <1% | 12 | $54.48 | |
| 80178 | <1% | 16 | $44.17 | |
| 85008 | <1% | 1,201 | $31.09 | |
| A9270 | Non-covered item or service | <1% | 55,411 | $30.44 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 22,542 | $29.56 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 21,477 | $23.83 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 11,721 | $20.11 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,704 | $19.74 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,047 | $15.41 |
| 84311 | <1% | 14 | $13.36 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 8,293 | $12.82 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,279 | $11.50 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,331 | $10.14 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,908 | $9.24 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 3,011 | $8.17 |
| 80305 | <1% | 309 | $7.55 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,401 | $7.33 |
| 83986 | <1% | 14 | $6.84 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,133 | $6.40 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,449 | $5.93 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,881 | $5.42 |
| 80365 | <1% | 258 | $5.05 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 6,327 | $3.88 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 737 | $3.84 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,142 | $3.07 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,124 | $2.62 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,620 | $1.88 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,381 | $1.60 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 858 | $1.38 |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 819 | $0.77 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,939 | $0.34 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 759 | $0.24 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 759 | $0.24 |
| J1815 | Injection, insulin, per 5 units | <1% | 1,865 | $0.14 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 114 | $0.02 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 3,014 | $0.00 |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | 0% | 489 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 297 | $0.00 |
| J0280 | Injection, aminophyllin, up to 250 mg | 0% | 1,253 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 74 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 2,939 | $0.00 |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 0% | 68 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 218 | $0.00 |
| 77001 | 0% | 41 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 91 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 43 | $0.00 |
| 91307 | 0% | 189 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 144 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 30 | $0.00 |
| 51798 | 0% | 30 | $0.00 | |
| 80329 | 0% | 77 | $0.00 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 159 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 29 | $0.00 |
| 99214 | Doctor's office visit, returning patient (more involved) | 0% | 85 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 77 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 24 | $0.00 |
| Q0247 | Injection, sotrovimab, 500 mg | 0% | 16 | $0.00 |
| 93000 | 0% | 16 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 34 | $0.00 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | 0% | 24 | $0.00 |
| J0706 | Injection, caffeine citrate, 5 mg | 0% | 14 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 198 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 1,619 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 476 | $0.00 |
| A4550 | Surgical trays | 0% | 90 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,516 | $0.00 |
| 80354 | 0% | 1,051 | $0.00 | |
| 88313 | 0% | 213 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 187 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 148 | $0.00 |
| 99001 | 0% | 54 | $0.00 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 0% | 128 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 111 | $0.00 |
| 87210 | 0% | 16 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 223 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 71 | $0.00 |
| 80362 | 0% | 20 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 15 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 185 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 171 | $0.00 |
| 80348 | 0% | 102 | $0.00 | |
| 36600 | 0% | 14 | $0.00 | |
| 82948 | 0% | 58 | $0.00 | |
| 76942 | 0% | 20 | $0.00 | |
| J7070 | Infusion, d5w, 1000 cc | 0% | 21 | $0.00 |
| 80346 | 0% | 55 | $0.00 | |
| 78434 | 0% | 55 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 165 | $0.00 |
| 81401 | 0% | 12 | $0.00 | |
| 91300 | 0% | 62 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 105 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 23 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 16 | $0.00 |
| 99152 | 0% | 37 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialELDERS, ROBERT (SECRETARY)
| Provider | Location | Paid |
|---|---|---|
| Prospect Manchester Hospital, INC. | Manchester, CT | $69.20M |
| Prospect Chartercare RWMC, LLC | Providence, RI | $57.10M |
| Prospect CCMC, LLC | Chester, PA | $40.89M |
| Prospect CT Medical Foundation, INC. | Manchester, CT | $34.07M |
| Prospect Rockville Hospital, INC. | Vernon, CT | $30.06M |
| Prospect Chartercare Sjhsri, LLC | North Providence, RI | $10.94M |
| Prospect DCMH, LLC | Drexel Hill, PA | $10.37M |
| Prospect CCMC, LLC | Chester, PA | $5.46M |
| Alta Los Angeles Hospitals, INC. | Los Angeles, CA | $5.42M |
| Prospect CCMC, LLC | Chester, PA | $5.03M |
| Prospect CCMC, LLC | Chester, PA | $3.71M |
| Prospect Chartercare Physicians, LLC | Cranston, RI | $2.31M |
| Prospect Echn Home Health, INC. | Vernon, CT | $1.75M |
| Prospect Waterbury Home Health, INC. | Watertown, CT | $1.30M |
| Prospect Health Access Network, INC. | Chester, PA | $1.22M |
| Alta Newport Hospital, LLC | Tustin, CA | $1.16M |
| Prospect Health Access Network, INC. | Crum Lynne, PA | $924K |
| Prospect Health Access Network, INC. | Chester, PA | $872K |
| Prospect Chartercare Sjhsri, LLC | North Providence, RI | $858K |
| Prospect Health Access Network, INC. | Drexel Hill, PA | $815K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.